B-cell receptor specific for influenza A H1 hemagglutinin (BCR-H1)

The B-cell receptor (BCR) specific for influenza A H1 hemagglutinin (HA) epitopes is a membrane-bound immunoglobulin complex that plays a pivotal role in the adaptive immune response to H1N1 influenza viruses (Nature, 2018). These receptors are responsible for the initial recognition of the HA protein, which is the primary surface antigen of the virus and is essential for viral entry into host cells (PubMed, 2021). Upon binding to specific epitopes on the HA head or stalk regions, the BCR initiates intracellular signaling cascades that lead to B-cell activation, proliferation, and differentiation into antibody-secreting plasma cells (Cell Reports, 2020). In the context of vaccination, these receptors are the primary targets for inducing protective immunity, with seasonal vaccines designed to stimulate BCRs that produce neutralizing antibodies (NIH, 2022). A significant challenge in targeting these receptors is the high mutation rate of the HA head region, which necessitates frequent vaccine updates to match circulating strains (Science Translational Medicine, 2019). Furthermore, the phenomenon of original antigenic sin can bias the BCR response toward epitopes encountered in previous infections, potentially limiting the effectiveness of vaccines against novel H1 variants (Journal of Experimental Medicine, 2022). Current therapeutic research focuses on identifying and stimulating BCRs that target broadly conserved epitopes to develop a universal influenza vaccine (Nature Communications, 2021).

Other names

H1-specific B-cell receptorHemagglutinin-specific BCRAnti-H1 BCRInfluenza A H1-specific BCR

Vaccine-mediated activation of H1-specific B-cell receptors induces clonal expansion and differentiation into plasma cells that secrete neutralizing antibodies against the hemagglutinin protein.